Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma.
暂无分享,去创建一个
G. Jerusalem | P. Rigo | G. Fillet | P. Paulus | Y. Beguin | M. Fassotte | F. Najjar
[1] F. Gherlinzoni,et al. The role of positron emission tomography (PET) in the management of lymphoma patients. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] G. Jerusalem,et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. , 1999, Blood.
[3] G. Jerusalem,et al. Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma. , 1999, Nuclear medicine communications.
[4] M Schwaiger,et al. Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. , 1998, Blood.
[5] J. D. van der Walt,et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. , 1998, Blood.
[6] E. Merkle,et al. Extranodal malignant lymphoma: detection with FDG PET versus CT. , 1998, Radiology.
[7] S. Reske,et al. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] J Kotzerke,et al. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging. , 1997, Radiology.
[9] D. Neuberg,et al. Early restaging gallium scans predict outcome in poor-prognosis patients with aggressive non-Hodgkin's lymphoma treated with high-dose CHOP chemotherapy. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] J. Keyes. SUV: standard uptake or silly useless value? , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[11] M. Kaminski,et al. Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT. , 1994, Radiology.
[12] O. Hoekstra,et al. Early treatment response in malignant lymphoma, as determined by planar fluorine-18-fluorodeoxyglucose scintigraphy. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[13] C. Tempany,et al. Lymphoma: monitoring tumor size and signal intensity with MR imaging. , 1993, Radiology.
[14] P. Stomper,et al. Gallium-67 imaging: a predictor of residual tumor viability and clinical outcome in patients with diffuse large-cell lymphoma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] G. Canellos,et al. Residual mass in lymphoma may not be residual disease. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] D. Weisenburger,et al. Chemotherapy for diffuse large-cell lymphoma--rapidly responding patients have more durable remissions. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] A. Wolf,et al. Metabolic trapping as a principle of oradiopharmaceutical design: some factors resposible for the biodistribution of [18F] 2-deoxy-2-fluoro-D-glucose. , 1978, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[18] K. Chishima. Studies on the origin of cancer cell. , 1961, Okajimas folia anatomica Japonica.
[19] O. Warburg. [Origin of cancer cells]. , 1956, Oncologia.